(IN BRIEF) Novonesis has launched Quara® Supreme, a thermostable enzymatic water-degumming solution developed to improve crude vegetable oil yield without generating free fatty acids. The biosolution enables processors to reduce typical degumming losses by as much as 2%*, while operating … Read the full press release
Posted in Business, Chemicals, Denmark, Germany, Industrial, News, Pharma & Biotech, Science, Technology
Tagged biosolutions innovation, drop-in biosolution, enzymatic degumming, flexible process integration, Hans Ole Klingenberg, no FFA generation, Novonesis, phosphorus reduction, Quara Supreme, refinery efficiency, soybean rapeseed canola oils, thermostable enzyme 85C, Thermostable enzyme from Novonesis boosts refinery efficiency and simplifies water-degumming operations, up to 2 percent extra oil, vegetable oil refining, water degumming yield loss
(IN BRIEF) GEA has launched the LYOVAC®ECO mode to significantly reduce the energy consumption of pharmaceutical freeze-drying systems, achieving validated savings of about 20 percent. The feature improves efficiency by dynamically adjusting condenser temperature and plate valve settings without affecting … Read the full press release
Posted in Business, Electronics & Machinery, Germany, Industrial, News, Pharma & Biotech, Technology
Tagged Add Better label, atmospheric spray drying, dynamic condenser temperature control, energy optimization, energy savings, GEA, GEA Advances Sustainable Pharmaceutical Freeze-Drying with TÜV-Verified LYOVAC ECO Mode, ISO 14021, liquid condenser, LYOAIR cooling system, LYOVAC ECO mode, LYOVAC FCM 500 D, microwave assisted drying, pharmaceutical freeze drying, plate valve control, sustainable processing technologies, Thomas Beutler, TÜV Rheinland
(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
(IN BRIEF) The Institute of Cancer Research, London, has announced the launch of the £42 million TRANSFORM trial, the UK’s largest prostate cancer screening study in more than 20 years. The first men have now been invited by their GPs … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 42 million research investment, Black men prostate cancer risk, cancer genetics, Caroline Moore, clinical research, Ealing Community Diagnostic Centre, early diagnosis, fast MRI, genetic saliva test, Hashim Ahmed, Institute of Cancer Research, Institute of Cancer Research Supports Major UK Study Testing Advanced Screening Methods for Prostate Cancer, Lucy Chappell, Mark Emberton, men's health, NHS screening programme, NIHR, prostate cancer screening, Prostate Cancer UK, PSA testing, Rakesh Heer, Rhian Gabe, Ros Eeles, screening inequalities, TRANSFORM trial, UK National Screening Committee, Wes Streeting
(IN BRIEF) AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong results from the Phase III KOMET trial, which showed a 20% … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 PN, Alexion, Annette Bakker, ASCO 2025, AstraZeneca, AstraZeneca Expands Koselugo’s Clinical Reach with New US Approval for Adults Living with Inoperable NF1 Plexiform Neurofibromas, Children’s Tumor Foundation, FDA approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, paediatric NF1 PN, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease treatment, regulatory approval, selumetinib, The Lancet, tumour response rate
(IN BRIEF) Team ULTRATOPIA from KU Leuven and Balgrist University Hospital has won the KUKA Innovation Award 2025 for a medical-robotics solution that uses ultrasound-guided collaborative robots to increase the accuracy and safety of pedicle screw placement during spinal surgery. … Read the full press release
Posted in Awards, Business, Electronics & Machinery, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Technology
Tagged Axel Weber, Balgrist University Hospital, collaborative robots, EU-funded research, FAROS project, healthcare robotics, KU Leuven, KUKA Innovation Award 2025, MEDICA trade fair, medical robotics, non radiative imaging, pedicle screw placement, precision surgery, robotic spinal surgery, Surgical Innovation, ultrasound guided surgery, ULTRATOPIA, ULTRATOPIA Researchers Develop Advanced Dual-Robot Ultrasound Method for Precision Spine Procedures, University of Zurich
(IN BRIEF) Novonesis has teamed up with thyssenkrupp Uhde to launch a revolutionary enzymatic fat-splitting process using the Lipura® Split enzyme, replacing traditional high-pressure thermal methods. By leveraging biosolutions at lower temperatures and atmospheric pressure, this method reduces energy and … Read the full press release
Posted in Business, Chemicals, Denmark, Germany, Industrial, News, Pharma & Biotech, Science, Technology
Tagged biosolutions, CAPEX reduction, energy efficiency, enzymatic fat-splitting, fatty acid production, Green Chemistry, Hans Ole Klingenberg, Lipura Split enzyme, Nadja Håkansson, Novonesis, oleochemical industry, pilot plant, process flexibility, Strategic Partnership Introduces Scalable, Sustainable Fat-Splitting Solution for Oleochemical Producers, sustainable manufacturing, ThyssenKrupp Uhde
(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged affordable biologics, biosimilar growth, Crohn's disease, FDA approval, JCV antibodies, Keren Haruvi, Labcorp partnership, multiple sclerosis, natalizumab-sztn, neurology portfolio, PML risk, Polpharma Biologics, REMS program, Sandoz, TYRUKO, TYRUKO Availability Marks Major Milestone in Affordable MS Care and Sandoz Biosimilar Leadership, Tysabri biosimilar, US launch
(IN BRIEF) At COMPAMED 2025, WACKER introduces several groundbreaking silicone solutions aimed at redefining medical adhesive and tubing performance while advancing environmental goals. The main attraction is SILPURAN® eco 2114, a biomethanol-based silicone gel adhesive produced under mass balance certification … Read the full press release
Posted in Business, Chemicals, Germany, Industrial, Marketing, News, Pharma & Biotech, Science, Technology
Tagged biomethanol silicone adhesive, carbon footprint reduction, COMPAMED 2025, Dr Ufuk Karabiyik, Düsseldorf, ELASTOSIL R plus 4360, ELASTOSIL R plus 4366, Healthcare Innovation, Ian Moore, Innovative Silicone Adhesives and Tubing Solutions Highlight WACKER’s COMPAMED 2025 Showcase, low-friction surface, medical technology, medical tubing, peristaltic pumps, REDcert2, silicone gel, SILPURAN eco 2114, sustainability, transdermal patches, WACKER
(IN BRIEF) The German Research Center for Artificial Intelligence (DFKI) and Mainz University Medical Center have initiated the MARK project to understand and predict the biological aging of the immune system using artificial intelligence. Funded by the Rhineland-Palatinate Ministry of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged aging research, AI in medicine, Andreas Dengel, artificial intelligence, biotechnology, blood stem cells, Center for Thrombosis and Hemostasis, Clemens Hoch, data science, DFKI, DFKI and Mainz researchers pioneer AI-driven insights into immune decline and age-related health risks, Germany, healthy aging, immune system aging, Kaiserslautern, life sciences, Mainz, Mainz University Medical Center, MARK project, MARK project combines artificial intelligence and biotechnology to advance healthy aging research in Rhineland-Palatinate, Molecular Analysis of Age-Related Risk Mechanisms, predictive health models, Rhineland-Palatinate Ministry of Science and Health, Wolfram Ruf
(IN BRIEF) ETH Zurich scientists have developed a novel iron supplement using oat protein nanofibrils coated with iron nanoparticles, offering nearly twice the absorption rate of standard iron sulphate supplements. The plant-based formula is vegan-friendly, tasteless, and easy to incorporate … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged anaemia, bioavailability, clinical study, dietary supplement, ETH Zurich, ETH Zurich researchers create breakthrough iron supplement with nearly double absorption efficiency, global health, iron deficiency, iron nanoparticles, Jiangtao Zhou, Michael B. Zimmermann, National University of Singapore, Nature Food, Nutrition, oat protein nanofibrils, Raffaele Mezzenga, selenium deficiency, sustainable nutrition, THAILAND, vegan supplement, zinc deficiency
(IN BRIEF) A major review led by the University of Liverpool and published in The BMJ finds no reliable evidence linking paracetamol use during pregnancy with autism or ADHD in children. Evaluating nine systematic reviews comprising 40 studies, researchers determined … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acetaminophen, ADHD, autism, Liverpool researchers find weak evidence behind claims linking paracetamol in pregnancy to child neurodevelopmental disorders, Louise Kenny, maternal health, medical research, medication safety, neurodevelopment, paracetamol, pregnancy, public health, Shakila Thangaratinam, The BMJ, UK science, University of Liverpool, Women’s Health
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical … Read the full press release
Posted in Artificial Intelligence (AI), Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Spain, Technology
Tagged AI in healthcare, Bio-Europe 2025, biotechnology, DaVitri platform, EIB, EIB Backs Overture Life’s Innovation to Make IVF More Efficient and Widely Available through AI, EIB Invests €20 Million in Overture Life to Advance AI-Based Fertility and IVF Technologies, European Innovation, European Investment Bank, fertility preservation, fertility technology, Hans Gangeskar, healthcare digitalisation, innovation funding, InvestEU, IVF automation, Karl Nehammer, life sciences, Overture Life, reproductive health, TechEU, Vienna, Women’s Health
(IN BRIEF) The European Medicines Agency (EMA), together with leading European healthcare professional and consumer organisations, has launched the #ItTakesATeam campaign to raise awareness of collective efforts in preventing and managing medicine shortages across the EU. The initiative, co-created with … Read the full press release
Posted in Healthcare, Management, Marketing, Media, News, Pharma & Biotech, United Kingdom
Tagged #ItTakesATeam, awareness campaign, EMA, EMA Unites European Healthcare Partners in #ItTakesATeam Campaign to Tackle Medicine Shortages, Emer Cooke, EU healthcare collaboration, European Association of Hospital Pharmacists, European Association of Nuclear Medicine, European Consumer Organisation, European Medicines Agency, European Paediatric Neurology Society, European Union of General Practitioners, healthcare professionals, Jorge Batista, medicine shortages, medicine supply chain, New EMA Awareness Initiative Highlights Collaborative Efforts Behind Managing Medicine Shortages Across Europe, patient safety, PGEU, public health, regulatory cooperation
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) Causeway Therapeutics, a University of Glasgow spin-out, has announced strong Phase 2 results for its novel microRNA therapy, TenoMiR®, used to treat tennis elbow. The study, involving 123 patients across the UK and USA, showed significant improvements in … Read the full press release
Posted in Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biotechnology, Causeway Therapeutics, Causeway Therapeutics Advances TenoMiR® Development Following Strong Phase 2 Results, clinical research, Declan Doogan, Derek Gilchrist, Glasgow City Council, Glasgow Riverside Innovation District, Iain McInnes, lateral epicondylitis, microRNA therapy, miR29a, Neal Millar, orthopaedic innovation, phase 2 trial, Phase 3 development, Promising Clinical Data Propel Glasgow Biotech Causeway Therapeutics Toward Full Development of TenoMiR®, Scott Rodeo, Scottish Enterprise, tendinopathy, tendon regeneration, tennis elbow, TenoMiR, University of Glasgow
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) Fresenius Medical Care will present multiple studies at ASN Kidney Week 2025, highlighting how hemodiafiltration (HDF) enhances clinical outcomes and how artificial intelligence is transforming kidney care. One of the featured oral presentations links HDF to a reduced … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Healthcare, Marketing, Pharma & Biotech, Science, Technology
Tagged AI Chatbot, AI in healthcare, ASN Kidney Week 2025, cardiovascular outcomes, clinical research, dialysis, digital innovation, Frank Maddux, Fresenius Medical Care, Fresenius Medical Care Highlights Real-World Benefits of Hemodiafiltration and AI Innovation at ASN Kidney Week in Houston, HDF, hemodiafiltration, HOUSTON, kidney disease, kidney therapy, nephrology, online high-volume HDF, patient care, precision medicine, Renal Research Institute
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?